Blood test for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer and are 18 or older.
- You are in good enough health to carry out daily activities (ECOG 0-1).
- You are willing to give multiple blood samples for the study.
- You are willing to provide tumor tissue from surgery or biopsy.
- You are in one of these groups: high-risk localized prostate cancer, active surveillance, biochemically recurrent cancer, or metastatic prostate cancer (hormone-sensitive or castration-resistant).
- You have not had another cancer (except certain skin cancers) in the last 3 years, and you are not currently on hormone therapy or other systemic treatment for prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for specific DNA repair changes in men with prostate cancer. It tests if these genetic features can help guide treatment decisions. You may join if you have high-risk localized, newly metastatic, or advanced prostate cancer and have tissue available for testing.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This study looks at whether a blood test that finds tiny amounts of remaining cancer (called minimal residual disease) can help predict how well treatment works for men with prostate cancer that has spread. If you qualify, you'll help researchers understand if this test can guide future treatment decisions.
This trial studies prostate cancer cells in the blood (“circulating tumor cells”) while you undergo planned prostate surgery. It may help doctors better understand prostate cancer and how it behaves early, which could guide future treatment decisions.
This trial enrolls adults who are being evaluated or treated for possible or confirmed prostate cancer and allows researchers to collect prostate tissue. It may help improve understanding of prostate cancer over the course of diagnosis and standard care.
This study is testing a new blood test that looks for cancer cells in your blood and checks if your tumor has a specific feature linked to DNA repair. The goal is to see if this blood test can help guide whether PARP inhibitor medicines—which target cancers with this feature—might work for you.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.